A Lung Adenocarcinoma with a STRN-ALK Rearrangement Was Poorly Responsive to Alectinib Treatment

被引：0
|
作者：
Iida, Y. [1 ]
Nakanishi, Y. [2 ]
Takahashi, N. [1 ]
Nishimaki, H. [2 ]
Nishizawa, T. [1 ]
Nakagawa, Y. [1 ]
Shimizu, T. [1 ]
Gon, Y. [1 ]
Masuda, S. [2 ]
Hashimoto, S. [1 ]
机构：
[1] Nihon Univ, Sch Med, Dept Internal Med, Div Resp Med, Tokyo, Japan
[2] Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Oncol Pathol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
non-small cell lung cancer; Resistance; STRN/ALK;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.03-009
引用
收藏
页码：S1953 / S1953
页数：1
相关论文
共 50 条
  • [1] STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
    Su, Cuiyun
    Jiang, Ya
    Jiang, Wei
    Wang, Huilin
    Liu, Sisi
    Shao, Yang
    Zhao, Wenhua
    Ning, Ruiling
    Yu, Qitao
    ONCOTARGETS AND THERAPY, 2020, 13 : 12515 - 12519
  • [2] STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
    Nagasaka, Misako
    Sarvadevabatla, Nagaratna
    Iwata, Shawn
    Ge, Yubin
    Sukari, Ammar
    Klosowski, Christian
    Yanagihara, Ronald
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (02):
  • [3] Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion
    Ren, Hongzheng
    Hou, Xiaonan
    Eiken, Patrick W.
    Zhang, Jin
    Pierson, Karlyn E.
    Nair, Asha A.
    Davila, Jaime I.
    Kovarikova, Helena
    Jang, Jin Sung
    Johnson, Sarah H.
    Molina, Julian R.
    Marks, Randolph S.
    Yang, Ping
    Yi, Joanne E.
    Mansfield, Aaron S.
    Jen, Jin
    CLINICAL LUNG CANCER, 2019, 20 (02) : E142 - E147
  • [4] Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
    Zeng, Hao
    Li, Yalun
    Wang, Ye
    Huang, Meijuan
    Zhang, Yan
    Tian, Panwen
    Li, Weimin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib
    Nakanishi, Yoko
    Masuda, Shinobu
    Iida, Yuko
    Takahashi, Noriaki
    Hashimoto, Shu
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : E202 - E204
  • [6] A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a STRN-ALK fusion by artificial intelligence and molecular modelling: a case report
    Barberis, Massimo
    Rappa, Alessandra
    de Marinis, Filippo
    Pelosi, Giuseppe
    Rocco, Elena Guerini
    Zhan, Yinxiu
    Tiana, Guido
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3807 - 3814
  • [7] STRN-ALK Fusion-Positive Case of Breast Cancer With Response to Alectinib
    Kelly, Andrew D.
    Wiklund, Tom
    Kononen, Juha
    Creeden, James
    JCO PRECISION ONCOLOGY, 2021, 5 : 1281 - 1284
  • [8] STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
    Zhang, Linlin
    Xiao, Ping
    Meng, Fanlu
    Zhong, Diansheng
    CURRENT ONCOLOGY, 2022, 29 (10) : 6749 - 6753
  • [9] Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion
    Nikitski, Alyaksandr, V
    Rominski, Susan L.
    Wankhede, Mamta
    Kelly, Lindsey M.
    Panebianco, Federica
    Barila, Guillermo
    Altschuler, Daniel L.
    Nikiforov, Yuri E.
    AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (11): : 2653 - 2661
  • [10] Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
    Zhu, Lucheng
    Ma, Shenglin
    Xia, Bing
    FRONTIERS IN ONCOLOGY, 2022, 12
12345